



OPEN HEALTH

ISPOR US 2024

MAY 5-8, 2024 | ATLANTA, GA | BOOTH 907

Short Course

TITLE	OPEN HEALTH PRESENTER	SESSION
Handling Uncertainty in Health Technology Assessment Processes	Elisabeth Fenwick	May 5, 2024 1:00 - 5:00 PM (EDT)

Breakout Session

TITLE	OPEN HEALTH PRESENTER	SESSION
Health Economists Want to Maximize QALYs, but Do Patients?	Marco Boeri	May 6, 2024 10:15 - 11:15 AM (EDT)

ISPOR Forum

TITLE	OPEN HEALTH PRESENTER	SESSION
Unlocking the Potential of OPEN Source Models: Strategies to Navigate Barriers in Development and Adoption	Elisabeth Fenwick	May 6, 2024 11:45 AM - 12:45 PM (EDT)

Poster Presentations

TITLE	OPEN HEALTH AUTHORS	SESSION
Budget Impact of Factor VIII Treatments for Hemophilia A in the United States	John Carter	May 6, 2024 10:30 AM - 1:30 PM (EDT)
Preferences and Attitudes of Healthcare Providers (HCPs) and Adult Healthcare Consumers (HCCs) Towards Pneumococcal Conjugate Vaccines (PCVs) in the United States (US)	Sophie Tsai Ning Ning Ana Martinez Rish Verma Jordana Schmier	May 6, 2024 10:30 AM - 1:30 PM (EDT)

www.openhealthgroup.com

© Copyright 2024 OPEN Health Company | All Rights Reserved

Poster Presentations

TITLE	OPEN HEALTH AUTHORS	SESSION
Clinical and Economic Value of a Biosimilar Portfolio to Stakeholders: A Conceptual Framework	Grace Fox Jennifer Stephens Mark Bernauer Bianca Jackson	May 6, 2024 3:30 - 6:30 PM (EDT)
Psychometric Validation of the QOL-B Respiratory Domain in Adults with Newly Diagnosed or Recurrent Mycobacterium avium Complex (MAC) Lung Disease: The ARISE and ENCORE Studies	Shauna McManus Lauren Podger	May 7, 2024 10:30 AM - 1:30 PM (EDT)
Budget Impact of Selinexor Combination Regimens in Previously Treated Multiple Myeloma	John Carter	May 7, 2024 3:30 - 6:30 PM (EDT)
Psychometric Validation of the PROMIS Fatigue-Short Form 7A in Adults with Newly Diagnosed or Recurrent Mycobacterium avium Complex (MAC) Lung Disease: The ARISE and ENCORE Studies	Shauna McManus Lauren Podger	May 7, 2024 3:30 - 6:30 PM (EDT)
A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab (NIVO+IPI) Vs Pembrolizumab Plus Axitinib (PEM+AXI) for the First-Line Treatment of Intermediate or Poor (I/P)-Risk Advanced Renal Cell Carcinoma Patients in Peru	Disha Jain	May 8, 2024 9:00 - 11:30 AM (EDT)

During ISPOR US, we will be hosting events where you will get the chance to connect with OPEN Health experts. Please see the details below.

OPEN Health client reception:

- **Date:** Monday, May 6, 2024
- **Time:** 6:00-7:00 PM (during the ISPOR welcome reception)
- **Location:** The OPEN Health booth, 907

OPEN Health recruitment reception:

- **Date:** Tuesday, May 7, 2024
- **Time:** 6:00-7:00 PM (during the ISPOR networking reception)
- **Location:** The OPEN Health booth, 907